In that view, the clinically available PKC inhibitor Sotrastaurin led to a diminished NF-κB activation and offered a significant anti-tumor effect in a subcutaneous CD79-mutated ABC DLBCL xenograft model (30). This evidence concerns the gene PRRT2 and neoplasm.